ANTI-ORAI1 ANTIGEN BINDING PROTEINS AND USES THEREOF

• US 20120231006A1
• Filed: 11/19/2010
• Published: 09/13/2012
• Est. Priority Date: 11/20/2009
• Status: Abandoned Application

• Current Assignee: Amgen Inc.
• Original Assignee: Amgen Inc.
• Inventors: Nguyen, Hung Q., Hu, Shaw-Fen Sylvia, Lin, Fen-Fen, Bi, Xiao-juan, McBride, Helen J.
• Application Number:
  US13/510,926
• Publication Number:
  US 20120231006A1
• Time in Patent Office: Days
• US Class Current: 424/139.1
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61P 1/00 Drugs for disorders of the alimentary tract or the digestive system
• CPC Class Codes: A61P 1/04 for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• CPC Class Codes: A61P 1/16 for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• CPC Class Codes: A61P 1/18 for pancreatic disorders, e.g. pancreatic enzymes
• CPC Class Codes: A61P 11/02 Nasal agents, e.g. decongestants
• CPC Class Codes: A61P 11/06 Antiasthmatics
• CPC Class Codes: A61P 17/06 Antipsoriatics
• CPC Class Codes: A61P 19/02 for joint disorders, e.g. arthritis, arthrosis
• CPC Class Codes: A61P 19/06 Antigout agents, e.g. antihyperuricemic or uricosuric agents
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: A61P 31/04 Antibacterial agents
• CPC Class Codes: A61P 33/02 Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 37/00 Drugs for immunological or allergic disorders
• CPC Class Codes: A61P 37/06 Immunosuppressants, e.g. drugs for graft rejection
• CPC Class Codes: A61P 37/08 Antiallergic agents antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14
• CPC Class Codes: A61P 43/00 : Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 7/02 : Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
• CPC Class Codes: A61P 7/04 : Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
• CPC Class Codes: A61P 9/00 : Drugs for disorders of the cardiovascular system
• CPC Class Codes: A61P 9/02 : Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
• CPC Class Codes: A61P 9/10 : for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• CPC Class Codes: C07K 14/47 : from mammals
• CPC Class Codes: C07K 16/28 : against receptors, cell surface antigens or cell surface determinants
• CPC Class Codes: C07K 2317/21 : from primates, e.g. man
• CPC Class Codes: C07K 2317/76 : Antagonist effect on antigen, e.g. neutralization or inhibition of binding
• CPC Class Codes: C07K 2317/92 : Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
• CPC Class Codes: C07K 2319/00 : Fusion polypeptide
• CPC Class Codes: C07K 2319/60 : containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]

Abstract

Disclosed is an isolated antigen binding proteins, such as but not limited to, an antibody or antibody fragment, that specifically bind to SEQ ID NO: 4, the amino acid sequence of extracellular loop 2 (ECL2) of human Orai1. Also disclosed are pharmaceutical compositions and medicaments comprising the antigen binding protein, isolated nucleic acid encoding it, vectors and host cells useful in methods of making it, and methods of using it in treating disorders or diseases in patients.

Claims

1-56. -56. (canceled)

57. An isolated antigen binding protein that specifically binds to SEQ ID NO:

4 in the extracellular loop (ECL) 2 of native human Orai1.

58. The isolated antigen binding protein of Claim 57 that:

(a) specifically binds to a native human Orai1 polypeptide,

(b) specifically binds to a polypeptide having an amino acid sequence consisting of

(i) SEQ ID NO;

210;

(ii) SEQ ID NO;

204;

(iii) SEQ ID NO;

192;

(iv) SEQ ID NO;

129;

or

(v) SEQ ID NO;

103; and

(c) does not specifically bind to a polypeptide having an amino acid sequence consisting of

(vi) SEQ ID NO;

91;

(vii) SEQ ID NO;

198;

(viii) SEQ ID NO;

113;

(ix) SEQ ID NO;

123;

(x) SEQ ID NO;

107;

or

(xi) SEQ ID NO;

117.

59. The isolated antigen binding protein of Claim 57 or Claim 58, wherein the isolated antigen binding protein comprises an antibody or antibody fragment.

60. The isolated antigen binding protein of Claim 59, comprising an immunoglobulin heavy chain variable region and an immunoglobulin light chain variable region, wherein:

(a) the heavy chain variable region comprises an amino acid sequence at least 95% identical to SEQ ID NO;

40, SEQ ID NO;

39, SEQ ID NO;

41, SEQ ID NO;

42, SEQ ID NO;

250, SEQ ID NO;

251;

SEQ ID NO;

252, SEQ ID NO;

253, SEQ ID NO;

254, or SEQ ID NO;

255;

or

(b) the light chain variable region comprises an amino acid sequence at least 95% identical to SEQ ID NO;

36, SEQ ID NO;

37, SEQ ID NO;

38, SEQ ID NO;

256, SEQ ID NO;

257, SEQ ID NO;

258, SEQ ID NO;

259, SEQ ID NO;

260, SEQ ID NO;

261, SEQ ID NO;

262, SEQ ID NO;

263, SEQ ID NO;

264, or SEQ ID NO;

265;

or

(c) the heavy chain variable region of (a) and the light chain variable region of (b).

61. The isolated antigen binding protein of Claim 59, comprising an immunoglobulin heavy chain variable region and an immunoglobulin light chain variable region, the heavy chain variable region comprising three complementarity determining regions designated CDRH1, CDRH2 and CDRH3, and the light chain variable region comprising three CDRs designated CDRL1, CDRL2 and CDRL3, wherein:

(a) CDRH1 comprises the amino acid sequence of SEQ ID NO;

43, SEQ ID NO;

44, SEQ ID NO;

45, SEQ ID NO;

266, or SEQ ID NO;

267;

(b) CDRH2 comprises the amino acid sequence of SEQ ID NO;

47, SEQ ID NO;

46, SEQ ID NO;

48, SEQ ID NO;

49, SEQ ID NO;

268, SEQ ID NO;

269, SEQ ID NO;

270, SEQ ID NO;

271, or SEQ ID NO;

272;

(c) CDRH3 comprises the amino acid sequence of SEQ ID NO;

50, SEQ ID NO;

51, SEQ ID NO;

52, SEQ ID NO;

273, SEQ ID NO;

274, SEQ ID NO;

275, SEQ ID NO;

276, or SEQ ID NO;

277;

(d) CDRL1 comprises the amino acid sequence of SEQ ID NO;

53, SEQ ID NO;

54, SEQ ID NO;

55, SEQ ID NO;

278, SEQ ID NO;

279, SEQ ID NO;

280, SEQ ID NO;

281, SEQ ID NO;

282, or SEQ ID NO;

283;

(e) CDRL2 comprises the amino acid sequence of SEQ ID NO;

56, SEQ ID NO;

57, SEQ ID NO;

284, SEQ ID NO;

285, SEQ ID NO;

286, SEQ ID NO;

287, SEQ ID NO;

288, or SEQ ID NO;

289; and

(f) CDRL3 comprises the amino acid sequence of SEQ ID NO;

58, SEQ ID NO;

59, SEQ ID NO;

290, SEQ ID NO;

291, SEQ ID NO;

292, SEQ ID NO;

293, SEQ ID NO;

294, SEQ ID NO;

295, SEQ ID NO;

296, or SEQ ID NO;

297.

62. The isolated antigen binding protein of Claim 59, comprising:

(a) an immunoglobulin heavy chain comprising the amino acid sequence of SEQ ID NO;

34, SEQ ID NO;

29, SEQ ID NO;

33, or SEQ ID NO;

35;

or

(b) an immunoglobulin light chain comprising the amino acid sequence of SEQ ID NO;

31, SEQ ID NO;

30, or SEQ ID NO;

32;

or

(c) the immunoglobulin heavy chain of (a) and the immunoglobulin light chain of (b).

63. The isolated antigen binding protein of Claim 57 or Claim 58,

wherein the isolated antigen binding protein inhibits human calcium response-activated calcium (CRAC) channel activity.

64. The isolated antigen binding protein of Claim 57 or Claim 58, wherein the isolated antigen binding protein inhibits release of IL-2, IFN-gamma, or both, in thapsigargin-treated human whole blood.

65. The isolated antigen binding protein of Claim 57 or Claim 58, wherein the protein inhibits NFAT-mediated expression.

66. The isolated antigen binding protein of Claim 57 or Claim 58, comprising an IgG1, IgG2, IgG3 or IgG4.

67. The isolated antigen binding protein of Claim 59, comprising a monoclonal antibody.

68. The isolated antigen binding protein of Claim 67, comprising a chimeric or humanized antibody.

69. The isolated antigen binding protein of Claim 67, comprising a human antibody.

70. The isolated antigen binding protein of Claim 59, comprising:

(a) an immunoglobulin heavy chain comprising the amino acid sequence of SEQ ID NO;

326, SEQ ID NO;

325, SEQ ID NO;

327, SEQ ID NO;

328, SEQ ID NO;

343, SEQ ID NO;

344, SEQ ID NO;

345, SEQ ID NO;

346, SEQ ID NO;

347, or SEQ ID NO;

348, or comprising the foregoing sequence from which one, two, three, four or five amino acid residues are lacking from the N-terminal or C-terminal, or both;

or

(b) an immunoglobulin light chain comprising the amino acid sequence of SEQ ID NO;

322, SEQ ID NO;

323, SEQ ID NO;

324, SEQ ID NO;

333, SEQ ID NO;

334, SEQ ID NO;

335, SEQ ID NO;

336, SEQ ID NO;

337, SEQ ID NO;

338, SEQ ID NO;

339, SEQ ID NO;

340, SEQ ID NO;

341, or SEQ ID NO;

342, or comprising the foregoing sequence from which one, two, three, four or five amino acid residues are lacking from the N-terminal or C-terminal, or both;

or

(c) the immunoglobulin heavy chain of (a) and the immunoglobulin light chain of (b).

71. A pharmaceutical composition comprising an antigen binding protein of Claim 57 or Claim 58;

and a pharmaceutically acceptable diluent, excipient or carrier.

72. An isolated nucleic acid that encodes the antigen binding protein of Claims 57, 58, or 59.

73. The isolated nucleic acid of Claim 72, wherein the isolated nucleic acid encodes an antigen binding protein comprising an immunoglobulin heavy chain variable region comprising an amino acid sequence at least 95% identical to SEQ ID NO:

40, SEQ ID NO;

39, SEQ ID NO;

41, SEQ ID NO;

42, SEQ ID NO;

250, SEQ ID NO;

251;

SEQ ID NO;

252, SEQ ID NO;

253, SEQ ID NO;

254, or SEQ ID NO;

255.

74. The isolated nucleic acid of Claim 72, wherein the isolated nucleic acid encodes an immunoglobulin heavy chain variable region and N-terminal signal sequence, the nucleic acid having SEQ ID NO:

23, SEQ ID NO;

25, or SEQ ID NO;

27.

75. The isolated nucleic acid of Claim 72, wherein the isolated nucleic acid encodes an antigen binding protein comprising an immunoglobulin light chain variable region comprising an amino acid sequence at least 95% identical to SEQ ID NO:

36, SEQ ID NO;

37, SEQ ID NO;

38, SEQ ID NO;

256, SEQ ID NO;

257, SEQ ID NO;

258, SEQ ID NO;

259, SEQ ID NO;

260, SEQ ID NO;

261, SEQ ID NO;

262, SEQ ID NO;

263, SEQ ID NO;

264, or SEQ ID NO;

265.

76. The isolated nucleic acid of Claim 72, wherein the isolated nucleic acid encodes an immunoglobulin light chain variable region and N-terminal signal sequence, the nucleic acid having SEQ ID NO:

15, SEQ ID NO;

17, or SEQ ID NO;

19.

77. The isolated nucleic acid of Claim 72, that encodes an immunoglobulin heavy chain variable region, wherein the isolated nucleic acid comprises coding sequences for three complementarity determining regions, designated CDRH1, CDRH2 and CDRH3, and wherein:

(a) CDRH1 comprises the amino acid sequence of SEQ ID NO;

43, SEQ ID NO;

44, SEQ ID NO;

45, SEQ ID NO;

266, or SEQ ID NO;

267;

(b) CDRH2 comprises the amino acid sequence of SEQ ID NO;

47, SEQ ID NO;

46, SEQ ID NO;

48, SEQ ID NO;

49, SEQ ID NO;

268, SEQ ID NO;

269,

SEQ ID NO;

270, SEQ ID NO;

271, or SEQ ID NO;

272; and

(c) CDRH3 comprises the amino acid sequence of SEQ ID NO;

50, SEQ ID NO;

51, SEQ ID NO;

52, SEQ ID NO;

273, SEQ ID NO;

274, SEQ ID NO;

275, SEQ ID NO;

276, or SEQ ID NO;

277.

78. The isolated nucleic acid of Claim 72, that encodes an immunoglobulin light chain variable region, wherein the isolated nucleic acid comprises coding sequences for three complementarity determining regions, designated CDRL1, CDRL2 and CDRL3, and wherein:

(a) CDRL1 comprises the amino acid sequence of SEQ ID NO;

53, SEQ ID NO;

54, SEQ ID NO;

55, SEQ ID NO;

278, SEQ ID NO;

279, SEQ ID NO;

280, SEQ ID NO;

281, SEQ ID NO;

282, or SEQ ID NO;

283;

(b) CDRL2 comprises the amino acid sequence of SEQ ID NO;

56, SEQ ID NO;

57, SEQ ID NO;

284, SEQ ID NO;

285, SEQ ID NO;

286, SEQ ID NO;

287, SEQ ID NO;

288, or SEQ ID NO;

289; and

(c) CDRL3 comprises the amino acid sequence of SEQ ID NO;

58, SEQ ID NO;

59, SEQ ID NO;

290, SEQ ID NO;

291, SEQ ID NO;

292, SEQ ID NO;

293, SEQ ID NO;

294, SEQ ID NO;

295, SEQ ID NO;

296, or SEQ ID NO;

297.

79. The isolated nucleic acid of Claim 72, wherein the isolated nucleic acid encodes an antigen binding protein comprising an immunoglobulin heavy chain comprising the amino acid sequence of SEQ ID NO:

29, SEQ ID NO;

33, SEQ ID NO;

34, or SEQ ID NO;

35.

80. The isolated nucleic acid of Claim 72, wherein the isolated nucleic acid encodes an antigen binding protein comprising an immunoglobulin light chain comprising the amino acid sequence of SEQ ID NO:

30, SEQ ID NO;

31, or SEQ ID NO;

32.

81. A vector comprising the isolated nucleic acid of Claim 72.

82. The vector of Claim 81, comprising an expression vector.

83. An isolated host cell comprising the expression vector of claim 82.

84. A method comprising:

(a) culturing the host cell of claim 83 in a culture medium under conditions permitting expression of the antigen binding protein encoded by the expression vector; and

(b) recovering the antigen binding protein from the culture medium.

85. A hybridoma, wherein the hybridoma produces the antigen binding protein of Claim 67.

86. A method, comprising:

(a) culturing the hybridoma of claim 85 in a culture medium under conditions permitting expression of the antigen binding protein by the hybridoma; and

(b) recovering the antigen binding protein from the culture medium.

87. A method of treating an immune disorder in a patient, comprising administering an effective amount of the antigen binding protein of any of Claims 57, 58, or 59 to the patient, wherein the immune disorder is selected from T cell-mediated autoimmunity, transplant rejection, graft versus host disease (GVHD), rheumatoid arthritis, multiple sclerosis, type-1 diabetes, systemic lupus erythematosus, psoriasis, inflammatory bowel disease (IBD), asthma, allergic rhinitis, eosinophilic disease, autoimmune central nervous system (CNS) inflammation, and inflammation-induced liver injury.

88. A method of treating a disorder related to venous or arterial thrombus formation in a patient, comprising administering an effective amount of the antigen binding protein of any of Claims 57, 58, or 59 to the patient, wherein the disorder is selected from arterial thrombosis, myocardial infarction, stroke, ischemic reperfusion injury, ischemic brain infarction, inflammation, complement activation, fibrinolysis, angiogenesis related to FXII-induced kinin formation, hereditary angioedema, bacterial infection of the lung, trypanosome infection, hypotensitive shock, pancreatitis, chagas disease, thrombocytopenia and articular gout.

89. A method of treating breast cancer in a patient, comprising administering an effective amount of the antigen binding protein of any of Claims 57, 58, or 59 to the patient.

90. The isolated antigen binding protein of Claim 57 or Claim 58, wherein the antigen binding protein specifically binds to SEQ ID NO:

2 expressed by a mammalian cell, with a K_d of 200 μ

M or less, as determined by a Kinetic Exclusion Assay.

91. The isolated antigen binding protein of Claim 57 or Claim 58, wherein the antigen binding protein specifically binds to SEQ ID NO:

2 expressed by a mammalian cell, with a K_d of 105 μ

M or less, as determined by a Kinetic Exclusion Assay.

92. The isolated antigen binding protein of Claim 57 or Claim 58, wherein the antigen binding protein specifically binds to SEQ ID NO:

2 expressed by a mammalian cell, with a KI of 50 μ

M or less, as determined by a Kinetic Exclusion Assay.